Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A. Stokke C, et al. Among authors: blakkisrud j. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1233-1241. doi: 10.1007/s00259-018-3964-9. Epub 2018 Feb 22. Eur J Nucl Med Mol Imaging. 2018. PMID: 29470615 Free PMC article. Clinical Trial.
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H. Kolstad A, et al. Among authors: blakkisrud j. Blood Adv. 2020 Sep 8;4(17):4091-4101. doi: 10.1182/bloodadvances.2020002583. Blood Adv. 2020. PMID: 32877524 Free PMC article. Clinical Trial.
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.
Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C. Løndalen A, et al. Among authors: blakkisrud j. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1902-1914. doi: 10.1007/s00259-020-05098-x. Epub 2020 Nov 16. Eur J Nucl Med Mol Imaging. 2021. PMID: 33196921 Free PMC article. Clinical Trial.
Radionuclides for Targeted Therapy: Physical Properties.
Stokke C, Kvassheim M, Blakkisrud J. Stokke C, et al. Among authors: blakkisrud j. Molecules. 2022 Aug 25;27(17):5429. doi: 10.3390/molecules27175429. Molecules. 2022. PMID: 36080198 Free PMC article. Review.
14 results